智通财经网·2025-10-28 14:49Core Insights - The company reported a revenue of 1.806 billion RMB for the first three quarters of 2025, representing a year-on-year growth of 42.06% [1] - The net loss attributable to shareholders narrowed to 596 million RMB, a decrease of 35.7% compared to the previous year [1] - The basic loss per share was 0.60 RMB [1] Revenue Growth - The increase in revenue was primarily driven by the sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®/LOQTORZI®), which generated approximately 1.495 billion RMB in sales in the domestic market, reflecting a year-on-year growth of about 40% [1] Cost Management and Financial Position - The company has implemented a "quality improvement and efficiency enhancement" action plan, focusing on cost control and resource allocation, which has significantly reduced the loss amount compared to the same period last year [1] - As of the end of the reporting period, the company had a total balance of cash and trading financial assets amounting to 3.270 billion RMB, indicating a strong liquidity position [1]